NCT01222286View on ClinicalTrials.gov

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

January 31, 2013

Conditions
Smoldering Multiple Myeloma
Interventions
DRUG

IPH2101

0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles

Trial Locations (5)

10029

Mount Sinai School of Medicine, New York

19104

Hospital of the University of Pennsylvania, Philadelphia

37203

Sarah Cannon Research Institute, Nashville

43210

Ohio State University, Columbus

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Innate Pharma
All Listed Sponsors
lead

Innate Pharma

INDUSTRY